Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 164
CHAPTER 8: BIBLIOGRAPHY
1. Yang YH, Rajaiah R, Lee DY, Zhongze M, Harry HY, Fong HS, Leo L, Berman BM,
Moudigl KD. Suppression of ongoing experimental arthritis by a Chines herbal
formula (Huo-Luo- Xiao-Ling Dan) involves changes in antigen-induced
immunological and biochemical mediators of inflammation. Evid Based Complement
Alternat Med. 2011; 1-10.
2. Kehlen A, Pachnio A, Thiele K, Langner J. Gene expression induced by interleukin-17
in fibroblast-like synoviocytes of patients with rheumatoid arthritis: upregulation of
hyaluronan-binding protein TSG-6. Arthritis Res Ther. 2003; 5(4):186-92.
3. Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am. 1990; 16(3):513-37.
4. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis
Res. 2002; 4(3):265-72.
5. Herman CJ, Allen P, Hunt WC, Prasad A, Brady TJ. Use of complementary therapies
among primary care clinic patients with arthritis. Prev Chronic Dis. 2004; 1(4):1-12.
6. Schwartzman S, Fleischmann R, Morgan JG. Do anti-TNF agents have equal efficacy
in patients with rheumatoid arthritis. Arthritis Res Ther. 2004; 6(2):3-11.
7. Axford SJ. Joint and bone infections. Rehum Int J. 2006; 34(10):405-12.
8. Colmegna I, Cuchacovich R, Espinoza LR. HLA-B27-associated reactive arthritis:
pathogenetic and clinical consideration. Clin Microbiol Rev. 2004; 17(2):348-69.
9. Veihelmann A, Hofbauer A, Krombach F, Dorger M, Maier M, Refior HJ et al.
Differential function of nitric oxide in murine antigen-induced arthritis. Rheumatology
(Oxford). 2002; 41(5):509-17.
10. Calvino B, Crepon-Bernard MO, Bars D. Parallel clinical and behavioural studies of
adjuvant-induced arthritis in the rat: possible relationship with chronic pain. Behav
Brain Res. 1987; 24(1):11-29.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 165
11. Ahamed S, Anuntiyo J, Malemud CJ, Haqqi TM. Biological basis for the use of
botanicals in osteoarthritis and rheumatoid arthritis; A Review. Evid Based
Complement Alternat Med. 2005; 2(3):301–8.
12. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned,
future directions. Nat Rev Drug Discov. 2007; 6(1):75-92.
13. Zhang RX, Fan AY, Zhou AN, Moudgil KD, Ma ZZ, Lee DY et al. Extract of the
Chinese herbal formula Huo Luo Xiao Ling Dan inhibited adjuvant arthritis in rats. J
Ethnopharmacol. 2009; 121(3):366-71.
14. The Ayurvedic Pharmacopoeia: A Dictionary of Indian Raw Materials and Industrial
product. CSIR: New Delhi; 1998. vol 4. p. 43-50.
15. Kapoor LD. Hand book of ayurvedic medicinal plants. New York: CRS Press; 2005. p.
1130-31.
16. Sharma PV. Dravyaguna-Vijana. Varanasi: Chaukhambha Bharati Academy; 2001. p.
295.
17. Loboa R, Prabhua SK, Dr Shirwaikara A, Shirwaikara A. Curcuma zedoaria Rosc.
(white turmeric) A review of its chemical pharmacological and ethnomedicinal
properties. J Pharm pharmacol. 2009; 61(1):13-21.
18. Wilsion E, Rajamanickam GV, Vyas N, Agarwal A, Dubey GP. Herbs used in siddha
medicine for arthritis - A Review. Ind. J. Trad. Knowl. 2007; 6(4):678-86.
19. FanY, Lao, Zhang R, Zhaou A, Berman BM, Barnes. Preclinical safety and evaluation
of the aqueous acetone extract of Chinies herbal formula modified Huo Luo Xiao
Ling dan. J Chines Interg Med. 2010; 8(5):438-47.
20. Funk JL, Frye JB, Oyarzo JN, Kuscuoglu N, Wilson J, McCaffrey G et al. Efficacy
and mechanism of action of turmeric supplements in the treatment of experimental
arthritis. Arthritis Rheum. 2006; 54(11):3452-64.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 166
21. Santosh KS, Manoj KP, Bokyung S, Kwang SA, Akira M, Gautam S et al. Curcumin,
demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones
differentially regulate anti-inflammatory and anti-proliferative responses through a
through a ROS-independent mechanism. Carcinogenesis. 2007; 28(8):1765–73.
22. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of
Curcuma longa a review of preclinical and clinical research. Altern Med Rev. 2009;
14(2):141-53.
23. Fulvio D, Acquisto J, Michael M, Sankar G. Inhibition of nuclear factor kappa B (NF-
KB) an emerging theam in anti-inflammatory therapies. Mol Inter. 2002; 2(1):22-35.
24. Delas HB, Hortelano S. Molecular basis of the anti-inflammatory effects of terpenoids.
Inflamm Allergy Drug Targets. 2009; 8(1):28-39.
25. U.S. Food and Drug administration. Guidance for Industry, Clinical development
program for drug, device and biological products for the treatment of rheumatoid
arthritis. [Online] 2006 [cited 2006 Nov]. Available from:
URL:htt://www.fda.gov/eder/guidance/index.htm
26. Henson EC, Brunson JG. Studies of adjuvant-induced arthritis in the albino rat (CFN
strain). Ann Rheum Dis. 1970; 29(2):185-89.
27. Mcdougall JJ, Karimian SM, Ferrell WR. Prolonged alteration of vasoconstrictor and
vasodilator responses in rat knee joints by adjuvant monoarthritis. Exp Physiol. 1995;
80(3):349-57.
28. Andersen ML, Santos EH, Seabra ML, Silva AA, Tufik S. Evaluation of acute and
chronic treatments with Harpagophytum procumbens on Freund's adjuvant-induced
arthritis in rats. J Ethnopharmacol. 2004; 91(2-3):325-30.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 167
29. Pezet S, Onte B,´ Gae N, Grannec I, Calvino B. Chronic Pain is Associated with
Increased TrkA Immunoreactivity in Spinoreticular Neurons. J Neurosci. 1999;
19(13):5482-92.
30. Bolon B, Campagnuolo G, Feige U. Duration of bone protection by a single
osteoprotegerin injection in rats with adjuvant-induced arthritis. Cell Mol Life Sci.
2002; 59(9):1569-76.
31. Kim EY, Moudgil KD. The determinants of susceptibility-resistance to adjuvant
arthritis in rats. Arthritis Res Ther. 2009; 11(4):239.
32. Kilimozhi D, Parthasarathy V, Amuthavalli N. Effect of Clerodendrum phlomidis on
adjuvant induced arthritis in rats - A radiographic densitometric analysis. Int J.
PharmTech Res. 2009; 1(4):1434-41.
33. Boettger MK, Leuchtweis J, Schaible HJ, Schmidt M. Videoradiographic analysis of
the range of motion in unilateral experimental knee joint arthritis in rats. Arthritis Res
Threp. 2011; 13(79):2-11
34. King RW. Rheumatoid Arthritis [Online]. 2006 [Cited 2006 Jul 13]. Available from:
URL:http://en.wikipedia.org/wiki
35. Beers MH, Berkow Rs, The Merk Manual of Diagnosis and Therapy. 7th
ed. USA:
Merck, Research Laboratories Pvt Ltd; 1999. p. 407–23.
36. Joseph TD, Robert LT, Gary CY, Gary RM, Barbara GW, Michael PL.
Pharmacotherapy-A Pathophysiologic Approach. 6th ed. New Delhi: McGraw-Hill
Medical Publication Division; 2005. p. 342-46.
37. Walker R, Edwards C. Clinical Pharmacy and Therapeutics. 5th ed. New York:
Churchill Living Stone; 2003. p. 779-96.
38. Kumar V, Dhingra S, Parle M. Rheumatoid Arthritis at a glance. Pharma Times. 2005;
37(11):53-55.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 168
39. Brunton LL, Lazo JS, Parker KL. The pharmacological basis of therapeutics. 11th ed.
New Delhi: McGrawHill medical publication division; 2006: p. 683-86.
40. Vogel HG, Vogel WH. Drug discovery and evaluation: Pharmacological assay. 3rd
ed. New York: springer-verlag Berlin Heidel berg; 2008. p. 1103-06.
41. Glynn LE. Pathology, pathogenesis, and aetiology of rheumatoid arthritis. Ann
Rheum Dis. 1972; 31(5): 412-20.
42. Kumar V, Abbas AK, Fausto N. Robbins and Cortran pathologic basis of disease. 7th
ed. Philadelphia: Saunders an imprint of elsevier; 2004. p. 1306-08.
43. Joan M, Bathon MD. Rheumatoid Arthritis Pathophysiology. Available from:
www.hopkins-arthritis.org.
44. Dayer JM, Fenner H. The role of cytokines and their inhibitors in arthritis. Baillieres
Clin Rheumatol. 1992; 6(2):485-516.
45. Masters SL, Simon A, Aksentijevich I, Kastner DL. autoinflammaticus: the molecular
pathophysiology of autoinflammatory disease. Annu Rev Immunol. 2009; 27:621-68.
46. Liu YL, Lin HM, Zou R, Wu JC, Han R, Raymond LN, at al. Suppression of complete
Freund's adjuvant-induced adjuvant arthritis by cobratoxin. Acta Pharmacol Sin. 2009;
30(2):219-27.
47. Hugh MD. A new model for rheumatoid arthritis?. Arthritis Res. 2000; 2:85–89.
48. Wang D, Miller SC, Sima M, Parker D, Buswell H, Goodrich KC et al. The
arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary
study. Pharm Res. 2004; 21(10):1741-49.
49. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The
American Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315-24.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 169
50. Daniel A, Neogi T, SilmanAJ, Funovits J, Felson DT, Bingham CO et al. 2010
Rheumatoid arthritis classification criteria. Artthritis rheum. 2010; 62(9):2569-81.
51. Symmons DP. Classification criteria for rheumatoid arthritis--time to abandon
rheumatoid factor. Rheumatology (Oxford). 2007; 46(5):725-26.
52. American College of Rheumatology Subcommittee on Rheumatoid Arthritis
Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update.
Arthritis Rheum. 2002; 46(2):328-46.
53. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am
Fam Physician. 2005; 72(6):1037-47.
54. Management of Early Rheumatoid Arthritis [Online] 2006 [cited 2006 July13].
Available from: URL:http;//www.sign.ac.uk
55. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close
DR et al. Efficacy of B-cell-targeted therapy with rituximab in patients with
rheumatoid arthritis. N Engl J Med. 2004; 350(25):2572-81.
56. Chatzidionysiou K, Van RF. When to initiate and discontinue biologic treatments for
rheumatoid arthritis?. J Int Med. 2011; 269(6): 614-25.
57. McCulloch CA, Downey GP, El-Gabalawy H. Signalling platforms that modulate the
inflammatory response: new targets for drug development. Nat Rev Drug Discov. 2006;
5(10):864-76.
58. Rang HP, Dale MM, Ritter JM, Flower RJ. Pharmacology. 6th ed. London: Churchill
Livingstone; 2003. p. 226-45.
59. Llamas KA, Tropical flowering plants, a guide to identification and cultivation. New
York: Timber Press; 2003. p. 367.
60. Balfour IB, Thaxter R, Blackman VH. Annals of botany. London: HighWire Press;
1956. vol 84. p. 413-15.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 170
61. Wilson B, Abraham G, Manju VS, Mathew M, Vimala B, Sundaresan S, Nambisan B.
Antimicrobial activity of Curcuma zedoaria and Curcuma malabarica tubers. J
Ethnopharmacol. 2005; 99(1):147-51
62. Yonzon, Minoba, Lee, Dong J, Yokochi, Toshihiro, Kawano, Yasuhiro, Nakahara.
Antimicrobial Activities of Essential Oils of Nepal. J Essential Oil Res. 2005; 17:107–
11.
63. Uechi S, Ishimine Y, Hongo F. Antibacterial activity of essential oil derived from
Curcuma sp. (Zingiberaceae) against food borne pathogenic bacteria and its heat-
stability. Sci Bull Faculty Agric. 2000; 47:129–36.
64. Bugno A. Antimicrobial efficacy of Curcuma zedoaria extract as assessed by linear
regression compared with commercial mouthrinses. Braz J Microbiol. 2007; 38:440–
45.
65. Ficker CE, Smith ML, Susiarti S, Leaman DJ, Irawati C, Arnason JT. Inhibition of
human pathogenic fungi by members of Zingiberaceae used by the Kenyah
(Indonesian Borneo). J Ethnopharmacol. 2003; 85(2-3):289-93.
66. Ansari MH, Ahmad S. Screening of some medicinal plants for antiamoebic action.
Fitoterapia. 1991; 62(2):171–75.
67. Champakaew D, Choochote W, Pongpaibul Y, Chaithong U, Jitpakdi A, Tuetun B et
al. Larvicidal efficacy and biological stability of a botanical natural product, zedoary
oil-impregnated sand granules, against Aedes aegypti (Diptera, Culicidae). Parasitol
Res. 2007; 100(4):729-37.
68. Navarro Dde F, Souza MM, Neto RA, Golin V, Niero R, Yunes RA. Phytochemical
analysis and analgesic properties of Curcuma zedoaria grown in Brazil.
Phytomedicine. 2002; 9(5):427-32.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 171
69. Matsuda H, Morikawa T, Toguchida I, Ninomiya K, Yoshikawa M. Inhibitors of nitric
oxide production and new sesquiterpenes, zedoarofuran, 4-epicurcumenol,
neocurcumenol, gajutsulactones A and B, and zedoarolides A and B, from Zedoariae
rhizome. Chem Pharm Bull (Tokyo). 2001; 49(12):1558-66.
70. Matsuda H, Tewtrakul S, Morikawa T, Nakamura A, Yoshikawa M. Anti-allergic
principles from Thai zedoary: structural requirements of curcuminoids for inhibition of
degranulation and effect on the release of TNF-alpha and IL-4 in RBL-2H3 cells. Org
Med Chem. 2004; 12(22):5891-98.
71. Raghuveer GPS, Md Majed A, Eranna D, Ramachandrasetty S. Evaluation of anti-
ulcer effect of root of Curcuma zedoaria in rats. Ind. J. Trad. Knowl. 2003; 2(1):375–
77.
72. Han BH. Screening of the inhibitory effect of herbal medicines on the platelet
activating factor (PAF) binding: 35 selected herbal medicines based on folk medicinal
informations. Yakhak Hoeji. 1995; 39:10–13.
73. Kim DI, Lee TK, Jang TH, Kim CH. The inhibitory effect of a Korean herbal medicine,
Zedoariae rhizoma, on growth of cultured human hepatic myofibroblast cells. Life Sci.
2005; 77(8):890-906.
74. Daduang S, Sattayasai N, Sattayasai J, Tophrom P, Thammathaworn A, Chaveerach
A, et al. Screening of plants containing Naja naja siamensis cobra venom inhibitory
activity using modified ELISA technique. Anal Biochem. 2005; 341(2):316-25.
75. Sangvanich P, Kaeothip S, Srisomsap C, Thiptara P, Petsom A, Boonmee A, Svasti J.
Hemagglutinating activity of Curcuma plants. Fitoterapia. 2007; 78(1):29-31.
76. Lee H, Lin JY. Anti-mutagenic activity of extracts from anticancer drugs in Chinese
medicine. Mutat Res. 1988; 204(2):229-34.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 172
77. Athima S, Arunporn I, Chawaboon D, Chatchai W, Niwat K, Pranee R. Cytotoxic
activity of thaimedicinal plants for cancer treatment. Songklanakarin J. Sci. Technol.
2005; 27(2):469-78.
78. Myoungae K. Cytotoxic activity of the extracts from Curcuma zedoaria. J Toxicol
Public Health. 2003; 19:293–96.
79. Matthes HW. Cytotoxic components of Zingiber zerumbet, Curcuma zedoaria and C.
domestica. Phytochemistry. 1980; 19:2643–50.
80. Mau JL. Composition and antioxidant activity of the essential oil from Curcuma
zedoaria. Food Chem. 2003; 82:583-91.
81. Nadkarni KM. Indian Materia Medica. Mumbai: Popular Prakashan Private Limited; 1999.
p. 418-19.
82. Makabe H, Maru N, Kuwabara A, Kamo T, Hirota M. Anti-inflammatory sesquiterpenes
from Curcuma zedoaria. Nat Prod Res. 2006; 20(7):680-85.
83. Ma X, Yu X, Han J. Application of off-line supercritical fluid extraction-gas
chromatography for the investigation of chemical constituents in Curcuma zedoaria.
Phytochem Anal. 1995; 6(6): 292-96.
84. Christiane RP. Seasonal variation and analgesic properties of different parts from
Curcuma zedoaria Roscoe (Zingiberaceae) grown in Brazil. J Natur forsch. 2006;
61:6–10.
85. Jang MK, Lee HJ, Kim JS, Ryu JH. A curcuminoid and two sesquiterpenoids from
Curcuma zedoaria as inhibitors of nitric oxide synthesis in activated macrophages.
Arch Pharm Res. 2004 Dec; 27(12):1220-25
86. Takano I, Yasuda I, Takeya K, Itokawa H. Guaiane sesquiterpene lactones from
Curcuma aeruginosa. Phytochemistry. 1995; 40(4):1197-1200.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 173
87. Shiobara Y, Asakawa Y, Kodama M, Takemoto T. 13-hydroxygermacrone and
curzeone, three sesquiterpenoids from Curcuma zedoaria. Phytochemistry. 1986 Sept;
25(6): 1351-53.
88. Gupta SK, Banerjee AB, Achari B. Isolation of Ethyl p-methoxycinnamate, the major
antifungal principle of Curcumba zedoaria. Lloydia. 1976; 39(4):218-22.
89. Hong CH, Kim Y, Lee SK. Sesquiterpenoids from the rhizome of Curcuma zedoaria.
Arch Pharm Res. 2001; 24(5):424-26.
90. Mau JL. Composition and antioxidant activity of the essential oil from Curcuma
zedoaria. Food Chem. 2003; 82(4):583-91.
91. Singh G, Om PS, Sumitra M. Chemical and biocidal investigations on essential oils of
some Indian Curcuma species. Progress in Crystal Growth and Characterization of
Materials. J. Sci Food Agri. 2002; 45(1-2):75–81.
92. Garg SN, Naquvi AA, Bansal RP, Bahl J R, Kumar S. Chemical composition of the
essential oil from the leaves of Curcuma zedoaria Rosc of Indian origin. J Essen oil
Res. 2005; 17:29-31.
93. Tohda C, Nakayama N, Hatanaka F, Komatsu K. Comparison of Anti-inflammatory
Activities of Six Curcuma Rhizomes: A Possible Curcuminoid-independent Pathway
Mediated by Curcuma phaeocaulis Extract. Evid Based Complement Alternat
Med. 2006; 3(2):255-60.
94. Purkayastha J, Subhan CN, Klinkby N. Essential oil of the rhizome of Curcuma
zedoaria (Christm) Rosc Native to northeast India. J Esse oil Res. 2006; 18:154–55.
95. Ozaki Y. Anti-inflammatory effect of Curcuma xanthorrhiza Roxb., and its active
principles. Chem Pharm Bull. 1990; 38:1045-48.
96. Paramapojn S, Gritsanapan W. Variation of curcuminoid in ethanolic extract of
Curcuma zedoaria rhizomes in Thailand by HPLC. Planta Medica. 2007; 73:797-804.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 174
97. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, Sartor RB.
Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene
expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999;
163(6):3474- 83.
98. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen
to clinic. Biochem Pharmacol. 2008; 75(4):787-809.
99. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine
production by human peripheral blood monocytes and alveolar macrophages.
Pharmacol Res. 1999; 39(1):41-47.
100. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK et al. Molecular
mechanisms underlying chemopreventive activities of anti-inflammatory
phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-
kappa B activation. Mutat Res. 2001; 481(5):243-68.
101. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA et al. Curcumin
blocks cytokine-mediated NF-kappa B activation and proinflammatory gene
expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999;
163(6):3474- 83.
102. Slater EP, Hesse H, Beato M. Regulation of transcription by steroide hormons. Ann.
Acad Science. 1994; 4(2):103-12.
103. Singh M, Pal M, Sharma RP. Biological activity of the labdane diterpenes. Planta
Med. 1999; 65(1):2-8.
104. Rasool M, Sabina EP. Antiinflammatory effect of the Indian ayurvedic herbal
formulation Triphala on adjuvant-induced arthritis in mice. Phytotherapy Research.
2007; 21(9):889-94.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 175
105. Pravin V, Gomase, Priti S. Shire, Nazim S, Amol B. Development and evaluation of
polyherbal formulation for anti-inflammatory activity. J Nat Prod Plant Resour. 2011;
1(1):85-90.
106. Himalaya Ayurvedic Gentle Face Wash Cream [Online] 2010 [cited 2010 April].
Available from: http://www matchless-gifts.com.
107. International Conference on Harmonization (ICH), Guidance for Industry, Q1A(R2):
Stability Testing of New Drug Substances and Products [Online] 2003 [cited 2003
Nov]. Available from: http://www.fda.gov/cber/gdlns/ichstab.pdf.
108. FDA, Draft Guidance for Industry, Stability Testing of Drug Substances and Drug
Products [Online] 1998 [cited 1998 June]. Available from
http://www.fda.gov/cber/gdlns/stabdft.pdf.
109. Sowbhagya HB, Smitha S, Sampathu SR, Krishnamurthy N, Bhattacharya S. Stability
of water-soluble turmeric colourant in an extruded food product during storage. J Food
Eng, 2005; 67(3):367-71.
110. Shrivastava SK, Rawat AS, Mehrotra S, Pushpangadan P. Botanical standardization of
three commercial important Curcuma species. J Sci Ind Reser. 2007 June; 66:450-56.
111. Khandelwal KR. Practical Pharmacognosy. Technique and experiments. 13th ed. Pune:
Nirali Prakashan; 2005. p. 157-60.
112. Kokate CK. Practical Pharmacognosy. 9th ed. Pune: Nirali Prakashan; 2002. p. 149-53.
113. Rajpal V. Standardization of botanicals. 2nd
ed. New Delhi: Business Horizons; 2011.
p. 1-5.
114. Mukherjee PK . Quality Control of Herbal Drugs- An Approach to Evaluation of
Botanicals. 1st ed. New Delhi: Business Horizons; 2002; p. 380.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 176
115. Handa SS, Sukhdev S. Khanuja SP, Dutt DR. Extraction Technologies for Medicinal
and Aromatic Plants. International centre for science and high technology Trieste,
[Online] 2008 [cited 2008 June]. Available from: http://www.unido.org/.
116. King MB, Bott TR, Extraction of natural products using near-critical solvents. 1st ed.
Bishopbriggs: Blackle academic professional an inprint of champan & hall; 1993. p.
140-56.
117. Finar IL, Finars Organic chemistry . Stereo Chemistry & the chemistry of Natural
Products. 5th ed. New Delhi: Dorling Kinbersley ltd; 2007.
118. OECD Guideline For Testing of Chemicals. Acute oral toxicity -Acute toxic Class
Method, 425, 2001. Annexure I. D, p 4.
119. Rispin A, Farrar D, Margosches E, Gupta K, Stitzel K, Carr G et al. Alternative
methods for the median lethal dose (LD 50) test: the up-and-down procedure for acute
oral toxicity. ILAR J. 2002; 43(4):233-43.
120. Syahmi AR, Vijayarathna S, Sasidharan S, Latha LY, 2, Kwan YP, Lau YL. Acute
oral toxicity and brine shrimp lethality of elaeis guineensis jacq., (oil palm leaf)
methanol extract. Molecules. 2010; 15(4):8111-21.
121. Butler SH, Godefroy F, Besson JM, Weil-Fugazza J. A limited arthritic model for
chronic pain studies in the rat. Pain. 1992; 48(1):73-81.
122. Dominique B, Jeanne WF, Lombard MC, Stephen H, Butler, Besson JM.
Monoarthritis induces complex changes in μ- δ- and κ-opioid binding sites in the
superficial dorsal horn of the rat spinal cord. European Journal of Pharmacology.
1992; 223(2):123-31.
123. Millecamps M, Jourdan D, Leger S, Etienne M, Eschalier A, Ardid D. Circadian
pattern of spontaneous behavior in monarthritic rats: a novel global approach to
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 177
evaluation of chronic pain and treatment effectiveness. Arthritis Rheum. 2005;
52(11):3470-8.
124. Chitme HR, Patel NP. Antiarthritis activity of Aristolochia bracteata extract in
experimental animals. Open Nature Product. 2009; 2:6-15.
125. De Castro Costa M, De Sutter P, Gybels J, Van Hees J. Adjuvant-induced arthritis in
rats: a possible animal model of chronic pain. Pain. 198; 10(2):173-85.
126. Kale SR, Kale RR. Practical Human Anatomy and Physiology. Pune: Nirali Prakashan;
1999.
127. Jain AK. Manual of Practical Physiology. New Delhi: Arya Publications; 1998. p. 22.
128. Mariappan G, Saha BP, Sutharson L, Singh A, Garg S, Pandey L et al. Analgesic,
anti-inflammatory, antipyretic and toxicological evaluation of some newer 3-methyl
pyrazolone derivatives. Saudi Pharm J. 2011; 19:115–22
129. Ramachandra SS, Quereshi AA, Viswanath Swamy AH, Patil T, Prakash T, Prabhu K
et al. Hepatoprotective activity of Calotropis procera flowers against paracetamol-
induced hepatic injury in rats. Fitoterapia. 2007; 78(7-8):451-54.
130. Dinesh M, Singh S, Joshi Y, Kadam V. Hepatoprotective activity of tuberous root of
Ipomoea digitata Linn against carbon tetrachloride induced hepatotoxicity. Int J
Pharma Sci Res. 2011; 2 (4):1034-39.
131. Kappor R, Kavimani S, Ravichandiran V, Sekhar K, Senthil R, Kumar M. Effect of
Indigofera aspalathoides on complete Freund’s adjuvant-induced arthritis in rats.
Pharm. Biol. 2009; 47(6):553-57.
132. Rej R, Vanderlinde RE. Assay of aspartate aminotransferase activity: effects of serum
and serum proteins on oxalacetate decarboxylation and dialysis. Clin Chem. 1974 Apr;
20(4):454-64.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 178
133. Parabathina RK, Muralinath E, Swamy LP, Hari VV, Krishna SK. Role of certain
flavonoids and vitamin-E against doxorubicin-induced oxiadative stress. J Chem
Pharm Res. 2011; 3(2):816-34.
134. Tietz N. Fundamentals of Clinical Chemistry. Philadelphia: WB Saunders Co; 1976.
135. Dipasquale G, Rassaert C, Welaj P, Gingold J, Schwartz E. Effects of multiple
treatments of isoxicam on organ weights and serum SGPT, AP, and BUN in adjuvant-
induced polyarthritic rats. Res Commun Chem Pathol Pharmacol. 1978; 19(3):529-32.
136. Harirforoosh S, Jamali F. Effect of inflammation on kidney function and
pharmacokinetics of COX-2 selective nonsteroidal anti-inflammatory drugs rofecoxib
and meloxicam. J Appl Toxicol. 2008; 28(7):829-38.
137. Young DS. Effects of Drugs on Clinical Laboratory Tests. 3rd ed. Philadelphia: WB
Saunders Co; 1990. p. 21-25.
138. Subramanian S. Diclofenac induced toxic manifestations on adjuvant-induced arthritic
rats pheripheral and reproductive organ of male wistar rats rattus norvegicus. J Toxicol
Environment Health Sci. 2009; 1(1):12-21.
139. Balis ME. Uric acid metabolism in man. Adv Clin Chem. 1976; 18:213-46
140. Trivedi R, Berta E, Rebar L. Enzymatic uric acid determination at 500nm by Trinder
method. Clin Chem. 1976; 22:1223.
141. Sanders GT, Pasman AJ, Hoek FJ. Determination of uric acid with uricase and
peroxidase. Clin Chim Acta. 1980; 101(2-3):299-303.
142. Shepherd MD, Mezzachi RD. Clinical chemistry principles and technics. Clin
Biochem Revs. 1983; 4(6):1-7.
143. Carlos A, Roncal, Wei M,
Byron C, Sirirat R, Xiaosen O. Effect of elevated serum uric
acid on cisplatin-induced acute renal failure. Am J of renal physiol. 2011; 301(1):42-
46.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 179
144. Browers LD. Text book of Clinical Chemistry. 3rd ed. Philadelphia: WB Sunders Co;
1980.
145. Bartel H. Serum creatinine determination without protein precipitation. Clin Chem
Acta. 1972; 37:193.
146. Arumugham R, Bose SM. Effect of Indomethacin and naproxen on the metabolism of
collagen in adjuvant-Induced Arthritis. J Rheumatol. 1981; 10(3):161-67.
147. Vijaya KN, Subramanian P. Protective effect of Semecarpus anacardium nut extract
against hyperammonemia in rats. J Herbal Med Toxicol. 2010; 4(2):77-82.
148. Total protein, Biuret method, end point. Erba diagnostic Mannheim GmbH kit,
Manufactured by Transasia Bio medicals LTD. Product code-FBCER0057.
149. Shirwaikar A, Somashekar AP, Udupa N, Udupa SL. Antiinflammatory activity and
free radical scavenging studies of Aristolochia bracteolate Lam. Ind J Pharma Sci.
2003; 65:67-9.
150. Fletcher DS, Widmer WR, Luell S, Christen A, Orevillo C, Shah S et al. Therapeutic
administration of a selective inhibitor of nitric oxide synthase does not ameliorate the
chronic inflammation and tissue damage associated with adjuvant-induced arthritis in
rats. J Pharmacol Exp Ther. 1998; 284(2):714-21.
151. Huskicl J, Zaciragic1 A, Babic N, Mulabegović N. Nitric oxide in serum and renal
tissue during compensatory renal hypertrophy in rats. Bosn J Basic Med Sci. 2006;
6(1):46-49.
152. Lam FF, Wong HH, Ng ES. Time course and substance P effects on the vascular and
morphological changes in adjuvant-induced monoarthritic rats. Int Immunopharmacol.
2004; 4(2):299-310.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 180
153. Demsar F, Van Dijke CF, Kirk BA, Kapila S, Peterfy CG, Roberts TP et al. Mapping
abnormal synovial vascular permeability in temporomandibular joint arthritis in the
rabbit using MRI. Br J Rheumatol. 1996; 35(3):23-5.
154. McDougall JJ, Karimian SM, Ferrell WR. Prolonged alteration of vasoconstrictor and
vasodilator responses in rat knee joints by adjuvant monoarthritis. Exp Physiol. 1995;
80(3):349-57.
155. Lam LY, Ferrell WR. Specific neurokinin receptors mediate plasma extravasation in
the rat knee joint. Br J Pharmacol. 199; 103(1): 1263-67.
156. Dimitrijević M, Laban O, Djurić VJ, Stanojević S, Miletić T, Kovacevic-Jovanović V
et al. Behavior and severity of adjuvant arthritis in four rat strains. Brain Behav
Immun. 2001; 15(3):255-65.
157. Sluka KA, Westlund KN. Behavioal and immunohistological changes in an
experimental arthritis model in rats. Pain. 1993; 55: 367-77.
158. Carlson RP, Datko LJ, Lynn ON, Frank D, Beideman R, Lewis AJ. Comparison of
inflammatory changes in established type-II collagen and adjuvant-induced arthritis
using outbred Wistar rats. Int J Immunopharmacol 1985; 7(6):811-26.
159. Chambon C, Paban V, Manrique C, Alescio-Lautier B. Behavioral and
immunohistological effects of cholinergic damage in immunolesioned rats: Alteration
of c-Fos and polysialylated neural cell adhesion molecule expression. Neuroscience.
2007;147(4):893-905.
160. Kulkarni SK. Hand book of experimental pharmacology. 3rd ed. New Delhi: Vallabh
prakashan; 2002. p. 128-31.
161. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of
sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis:
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 181
comparison of efficacy in animal models with human clinical data. Arthritis
Rheum. 1999; 42(3): 498-506.
162. Severijnen AJ, Kleef R, Grandia AA, Kwast TH, Hazenberg MP. Histology of joint
inflammation induced in rats by cell wall fragments of the anaerobic intestinal
bacterium eubacterium aerofaciens. Rheumatol Int. 1991; 11(4-5):203-8.
163. Ekambaram S, Perumal SS, Subramanian V. Evaluation of antiarthritic activity of
Strychnos potatorum Linn seeds in Freund's adjuvant induced arthritic rat model.
Complement Altern Med. 2010; 13;10:56.
164. Hamada T, Arima N, Shindo M, Sugama K, Sasaguri Y. Suppression of adjuvant
arthritis of rats by a novel matrix metalloproteinase-inhibitor. Br J Pharmacol. 2000;
131(8):1513-20.
165. Department of Ayurveda, Yoga, & Naturopathy, Unani, Siddha and Homeopathy,
Ministry of health and Family Welfare, Government of India. Guidelines for Toxicity
Investigation of Herbal Medicine (Annexure-1) [Online] 2005 [cited 2005 Aug 19].
Available from: URL:http://indianmedecine.nic.in.
166. Popp T, Peddinghaus RM. Antirheumatic drug profiles evaluated in the adjuvant
arthritis of rats by multiparameter analysis. 1994; 42:50-5.
167. Bailey SA, Zidell RH, Perry RW. Relationships between organ weight and body/brain
weight in the rat: what is the best analytical endpoint. Toxicol Pathol. 2004; 32(4):448-
66.
168. Gepdiremen A, Mshvildadze V, Bakuridze K, Elias R. Effects of Leontice smirnowii
tuber monodesmosides and crude extract in carrageenan and histamine-induced acute
inflammation model of rats. Phytomedicine. 2006; 13(9-10):728-31.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 182
169. Vinegar R, Truax JF, Selph JL, Johnston PR, Venable AL, McKenzie KK. Pathway to
carrageenan-induced inflammation in the hind limb of the rat. Fed Proc. 1987;
46(1):118-26.
170. MacGlashan DJ. Histamine: A mediator of inflammation. J Allergy Clin
Immunol. 2003; 112(4):53-9.
171. Permin H, Skov PS, Norn S, Geisler A, Klysner R, Andersen V et al. Possible role of
histamine in rheumatoid arthritis, treatment with cimetidine and mepyramine.
Allergy. 1981; 36(6):435-36.
172. Huang M, Xie YY, Ding GH. Acupoint-injection of histamine induced analgesic effect
in acute adjuvant-induced-arthritis rats. Zhen Ci Yan Jiu. 2010; 35(2):99-103.
173. Asghari G, Mostajeran A, Shebli M. Curcuminoid and essential oil components of
turmeric at different stages of growth cultivated in Iran. Res Pharma Sci. 2009 April;
4(1):55-61.
174. Chearwae W, Wu CP, Chu HY, Lee TR, Ambudkar SV, Limtrakul P. Curcuminoids
purified from turmeric powder modulate the function of human multidrug resistance
protein 1 (ABCC1). Cancer Chemother Pharmacol. 2006; 57(3):376-88.
175. Brain. KR, Turner TD. The Practical evaluation of pharmaceuticals. 2nd ed. Bristol:
Wright scientechnica; 1975.
176. Stahl E. Thin Layer Chromatography - A laboratory Handbook. 2nd ed. New York:
Springer-Verlag Berlin Heidelberg; 1990.
177. Kasture AV, Wadodkar SG, Mahadik KR, More HN. A textbook of Pharmaceutical
analysis. (Instrumental methods). 2nd ed. Pune: Nirali Prakashan; 1997. p. 18-27.
178. Gupta AP, Gupta MM, Kumar S. Simultaneous determination of curcuminoids in
Curcuma samples using high performance thin layer chromatography. Liq. Chrom. &
Rel. Technol. 1999; 22(10):1561–69.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 183
179. Lou Y, Zhang H, He H, Peng K, Kang N, Wei X, et al. Isolation and identification of
phase 1 metabolites of curcumol in rats. Drug Metab Dispos. 2010; 38(11):2014-22.
180. Mara EM, Braga M, Angela A, Meireles. Accelerated solvent extraction and fractioned
extraction to obtain the Curcuma longa volatile oil and oleoresin. J Food Proce
Eng .2007; 30(4): 501–21.
181. Olga N, Pozharitskaya, Svetlana A, Ivanova, Alexander N, Shikov et al. Separation
and free radical-scavenging activity of major curcuminoids of Curcuma longa using
HPTLC-DPPH method. Phytochemical Analysis. 2008; 19(3): 236–43.
182. Katsuyama Y, Kita T, Horinouchi S. Identification and characterization of multiple
curcumin synthases from the herb Curcuma longa. FEBS Lett. 2009; 583(17):2799-
803.
183. Chearwae W, Anuchapreedac S, Nandigama K, Ambudkar SV, Limtrakul P.
Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by
curcumin I, II, and III purified from Turmeric powder. Bio Chem Pharm. 2004; 68(5):
2043–52.
184. Chethan KM. Turmerin, a protein from Curcuma longa L. prevent oxidative organ
damage against Naja naja venom phospholipase A2 in experimental animal. J Pharm
Clin Res. 2010; 3(1):29-34.
185. The Department of Health. British Pharmacopoeia. London: Health Ministry; 2008.
vol 2, p. 2360.
186. Mithal BM. Text book of Pharmaceutical Formulations. 6th ed. Delhi: Vallabh
Prakashan; 1997. p. 214.
187. Note for guidance on stability testing of new drug substance and products [Online]
2003 [cited 2003 Aug]. Available from:http://www emea.eu.int.
Chapter 8 Bibliography
Faculty of Pharmacy, Belgaum KLE University 184
188. Natalie Mc Clure, Matrix Pharmaceutical Inc. Stability studies an overview of ICH
guidelines for drug products [Online] 1957 [cited 1957 Oct 30]. Available from http://
www.mcclurenet.com.
189. Rainsford KD. Adjuvant polyarthritis in rats: is this a satisfactory model for screening
anti-arthritic drugs. Agents Actions. 1982; 12(4):452-8.
190. Patil KR, Patil CR, Jadhav RB, Mahajan VK, Patil PR, Gaikwad PS. Anti-arthritic
Activity of bartogenic acid isolated from fruits of Barringtonia racemosa Roxb.
(Lecythidaceae). Evid Based Complement Alternat Med. 2009 Sep 21.
191. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative
medicine use among adults: United States, 2002. Adv Data. 2004; (343):1-19.
192. Winter CA, Risley EA, Silber RH. Antiinflammatory activity of indomethacin and
plasma corticosterone in rats. J Pharmacol Exp Ther.1968; 162(1):196-201.